Literature DB >> 9699870

Estrogen regulation of cell cycle progression in breast cancer cells.

O W Prall1, E M Rogan, R L Sutherland.   

Abstract

Estrogens are potent mitogens in a number of target tissues including the mammary gland where they play a pivotal role in the development and progression of mammary carcinoma. The demonstration that estrogen-induced mitogenesis is associated with the recruitment of non-cycling, G0, cells into the cell cycle and an increased rate of progression through G1 phase, has focused attention on the estrogenic regulation of molecules with a known role in the control of G1-S phase progression. These experiments provide compelling evidence that estrogens regulate the expression and function of c-Myc and cyclin D1 and activate cyclin E-Cdk2 complexes, all of which are rate limiting for progression from G1 to S phase. Furthermore, these studies reveal a novel mechanism of activation of cyclin E-Cdk2 complexes whereby estrogens promote the formation of high molecular weight complexes lacking the CDK inhibitor p21. Inducible expression of either c-Myc or cyclin D1 can mimic the effects of estrogen in activating the cyclin E-Cdk2 complexes and promoting S phase entry, providing evidence for distinct c-Myc and cyclin D1 pathways in estrogen-induced mitogenesis which converge on the activation of cyclin E-Cdk2. These data provide new mechanistic insights into the known mitogenic effects of estrogens and identify potential downstream targets that contribute to their role in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699870     DOI: 10.1016/s0960-0760(98)00021-1

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  50 in total

1.  Up-regulation of steroid sulphatase activity in HL60 promyelocytic cells by retinoids and 1alpha,25-dihydroxyvitamin D3.

Authors:  P J Hughes; L E Twist; J Durham; M A Choudhry; M Drayson; R Chandraratna; R H Michell; C J Kirk; G Brown
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 2.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 3.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

4.  Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.

Authors:  Tianhong Li; Federica Sotgia; Magalis A Vuolo; Maomi Li; Wan Cai Yang; Richard G Pestell; Joseph A Sparano; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

5.  Estrogen regulates JNK1 genomic localization to control gene expression and cell growth in breast cancer cells.

Authors:  Miao Sun; Gary D Isaacs; Nasun Hah; Nina Heldring; Elizabeth A Fogarty; W Lee Kraus
Journal:  Mol Endocrinol       Date:  2012-03-22

6.  Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.

Authors:  Seetharaman Balasenthil; Ratna K Vadlamudi
Journal:  J Biol Chem       Date:  2003-04-07       Impact factor: 5.157

Review 7.  Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Endocr Relat Cancer       Date:  2011-07-04       Impact factor: 5.678

8.  The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha.

Authors:  Archana Dhasarathy; Masahiro Kajita; Paul A Wade
Journal:  Mol Endocrinol       Date:  2007-08-30

9.  Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.

Authors:  Mathieu Dalvai; Kerstin Bystricky
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.

Authors:  Stephanie J Ellison-Zelski; Elaine T Alarid
Journal:  Mol Cancer       Date:  2010-09-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.